Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio — Stella

Recruiting

Back to Bile Duct Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Key details

Phase

Safety & dosing

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

AstraZeneca, Sirtex Medical

Enrollment target

~30 participants

Started

February 2024

Primary completion

December 2026

Age range

18 Years and older

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov